Table Info

Table 3.

Bile-based liquid biopsy in BTCs

Authors	Number of patients	Type of analysis on bile cfDNA	Relevance	References
Shen et al.	10	Targeted deep sequencing	Bile-based liquid biopsy features high concordance with blood samples and tumor tissue	[45]
Gou et al.	28	qPCR	Bile-based liquid biopsy features high concordance with blood samples and tumor tissue	[46]
Driescher et al.	35	NGS (qPCR for KRAS analysis)	Bile-based liquid biopsy features high concordance with blood samples and tumor tissue and can outperform blood-based biopsy	[47]
Han et al.	42	qPCR	Detection of KRAS mutations in bile samples predicts poorer prognosis	[48]

Declarations

Author contributions

GA, VN, FP and EFG contributed conception and design of this review; GA, VN, FP wrote the first draft of the manuscript; GA and EFG revised the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Louis C, Papoutsoglou P, Coulouarn C. Molecular classification of cholangiocarcinoma. Curr Opin Gastroenterol. 2020;36:57–62. [DOI] [PubMed]

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95–111. [DOI] [PubMed] [PMC]

Ghouri YA, Mian I, Blechacz B. Cancer review: cholangiocarcinoma. J Carcinog. 2015;14:1. [DOI] [PMC] [PubMed]

DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–62. [DOI] [PubMed] [PMC]

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61. [DOI] [PubMed]

Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–80. [DOI] [PubMed]

Nakanuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol. 2015;29:277–93. [DOI] [PubMed]

Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39:7–18. [DOI] [PubMed]

Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, et al. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer. 2012;1:21–32. [DOI] [PubMed]

10.

Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25. [DOI] [PubMed]

11.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al.; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81. [DOI] [PubMed]

12.

Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al.; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690–701. [DOI] [PubMed] [PMC]

13.

Mondaca S, Nervi B, Pinto M, Abou-Alfa GK. Biliary tract cancer prognostic and predictive genomics. Chin Clin Oncol. 2019;8:42. [DOI] [PubMed] [PMC]

14.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122:3838–47. [DOI] [PubMed]

15.

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–84. [DOI] [PubMed] [PMC]

16.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807. Erratum in: Lancet Oncol. 2020;21:e462. [DOI] [PubMed] [PMC]

17.

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31. [DOI] [PubMed] [PMC]

18.

Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and translational research challenges in biliary tract cancers. Curr Med Chem. 2020;27:4756–77. [DOI] [PubMed]

19.

Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, Roehrl MHA, Barrera-Saldaña HA. The dawn of the liquid biopsy in the fight against cancer. Oncotarget. 2017;9:2912–22. [DOI] [PMC] [PubMed]

20.

Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol. 2018;10:1758835918794630. [DOI] [PMC] [PubMed]

21.

Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39:95. Erratum in: J Exp Clin Cancer Res. 2020;39:120. [DOI] [PubMed] [PMC]

22.

Shotton R, Lamarca A, Valle J, McNamara MG. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: a review. World J Gastrointest Oncol. 2021;13:1073–85. [DOI] [PubMed] [PMC]

23.

Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: current status and future perspectives. World J Gastrointest Oncol. 2021;13:332–50. [DOI] [PMC] [PubMed]

24.

Kumari S, Tewari S, Husain N, Agarwal A, Pandey A, Singhal A, et al. Quantification of circulating free DNA as a diagnostic marker in gall bladder cancer. Pathol Oncol Res. 2017;23:91–7. [DOI] [PubMed]

25.

Wasenang W, Chaiyarit P, Proungvitaya S, Limpaiboon T. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clin Epigenetics. 2019;11:39. [DOI] [PubMed] [PMC]

26.

Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, et al. Circulating tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol. 2019;3:1–9. [DOI] [PubMed]

27.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5:1040–8. [DOI] [PubMed] [PMC]

28.

Andersen RF, Jakobsen A. Screening for circulating RAS/RAF mutations by multiplex digital PCR. Clin Chim Acta. 2016;458:138–43. [DOI] [PubMed]

29.

Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst. 2020;112:200–10. [DOI] [PubMed]

30.

Chen C, Wang T, Yang M, Song J, Huang M, Bai Y, et al. Genomic profiling of blood-derived circulating tumor DNA from patients with advanced biliary tract cancer. Pathol Oncol Res. 2021;27:1609879. [DOI] [PubMed] [PMC]

31.

Csoma SL, Bedekovics J, Veres G, Árokszállási A, András C, Méhes G, et al. Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing. Cancers (Basel). 2022;14:233. [DOI] [PubMed] [PMC]

32.

Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, et al. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021;148:702–12. [DOI] [PubMed] [PMC]

33.

Ettrich TJ, Schwerdel D, Dolnik A, Beuter F, Blätte TJ, Schmidt SA, et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep. 2019;9:13261. [DOI] [PubMed] [PMC]

34.

Lamarca A, McNamara MG, Hubner R, Valle JW. Role of ctDNA to predict risk of recurrence following potentially curative resection of biliary tract and pancreatic malignancies [abstract]. J Clin Oncol. 2021;39:336. [DOI]

35.

Aguado E, Abou-Alfa GK, Zhu AX, Macarulla T, Fan B, Nejad P, et al. IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study [abstract]. J Clin Oncol. 2020;38:4576. [DOI]

36.

Yang X, Hu Y, Yang K, Wang D, Lin J, Long J, et al. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer. 2021;9:e001942. [DOI] [PubMed] [PMC]

37.

Yarlagadda B, Kamatham V, Ritter A, Shahjehan F, Kasi PM. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. NPJ Precis Oncol. 2019;3;19. [DOI] [PubMed] [PMC]

38.

Yu Y, Liu Q, Li W, Qu Y, Zhang Y, Liu T. Identification of a novel EHBP1-MET fusion in an intrahepatic cholangiocarcinoma responding to crizotinib. Oncologist. 2020;25:1005–8. [DOI] [PubMed] [PMC]

39.

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7:252–63. [DOI] [PubMed] [PMC]

40.

Goyal L, Shi L, Liu LY, de la Cruz FF, Lennerz JK, Raghavan S, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9:1064–79. [DOI] [PubMed] [PMC]

41.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48. [DOI] [PubMed]

42.

Gowda GAN. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark Med. 2010;4:299–314. [DOI] [PubMed]

43.

Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology. 2014;60:896–907. Erratum in: Hepatology. 2014;60:2135. [DOI] [PubMed] [PMC]

44.

Shi C, Chandrasekaran A, Thuluvath PJ, Karikari C, Argani P, Goggins M, et al. Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology. J Mol Diagnostics. 2009;11:583–9. [DOI] [PubMed] [PMC]

45.

Shen N, Zhang D, Yin L, Qiu Y, Liu J, Yu W, et al. Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer. Oncol Rep. 2019;42:549–60. [DOI] [PubMed] [PMC]

46.

Gou Q, Zhang CZ, Sun ZH, Wu LG, Chen Y, Mo ZQ, et al. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open. 2021;6:100275. [DOI] [PubMed] [PMC]

47.

Driescher C, Fuchs K, Haeberle L, Goering W, Frohn L, Opitz FV, et al. Bile-based cell-free DNA analysis is a reliable diagnostic tool in pancreatobiliary cancer. Cancers (Basel). 2020;13:39. [DOI] [PubMed] [PMC]

48.

Han JY, Ahn KS, Kim TS, Kim YH, Cho KB, Shin DW, et al. Liquid biopsy from bile-circulating tumor DNA in patients with biliary tract cancer. Cancers (Basel). 2021;13:4581. [DOI] [PubMed] [PMC]

49.

Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, et al. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut. 2022;71:1141–51. [DOI] [PubMed] [PMC]

50.

Puik JR, Meijer LL, Le Large TY, Prado MM, Frampton AE, Kazemier G, et al. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics. 2017;18:1343–58. [DOI] [PubMed]

51.

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24. [DOI] [PubMed]

52.

Finnegan EF, Pasquinelli AE. MicroRNA biogenesis: regulating the regulators. Crit Rev Biochem Mol Biol. 2013;48:51–68. [DOI] [PubMed] [PMC]

53.

Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget. 2015;6:5932–46. [DOI] [PubMed] [PMC]

54.

He Y, Jiang X, Chen J. The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 2014;33:3887–93. [DOI] [PubMed]

55.

Wu X, Xia M, Chen D, Wu F, Lv Z, Zhan Q, et al. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma. Tumor Biol. 2016;37:15019–29. [DOI] [PubMed]

56.

Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS One. 2015;10:e0139305. [DOI] [PubMed] [PMC]

57.

Han HS, Kim MJ, Han JH, Yun J, Kim HK, Yang Y, et al. Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2020;19:41–50. [DOI] [PubMed]

58.

Cheng Q, Feng F, Zhu L, Zheng Y, Luo X, Liu C, et al. Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma. Sci Rep. 2015;5:16103. [DOI] [PubMed] [PMC]

59.

Wang LJ, Zhang KL, Zhang N, Ma XW, Yan SW, Cao DH, et al. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget. 2015;6:18631–40. [DOI] [PubMed] [PMC]

60.

Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113–29. [DOI] [PubMed]

61.

Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007;282:8256–64. [DOI] [PubMed]

62.

Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013;8:e77623. [DOI] [PubMed] [PMC]